Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ceritinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK known ✓ | Q9UM73 | 20/20 | 0.98 |
| ▸ | NPM1 known ✓ | P06748 | 1/20 | 0.98 |
| ▸ | EML4 known ✓ | Q9HC35 | 1/20 | 0.98 |
| ▸ | INSR | P06213 | 11/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.98 |
| ▸ | PLK4 | O00444 | 1/20 | 0.98 |
| ▸ | BUB1B | O60566 | 1/20 | 0.98 |
| ▸ | JAK2 | O60674 | 1/20 | 0.98 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.98 |
| ▸ | ABL1 | P00519 | 1/20 | 0.98 |
| ▸ | EGFR | P00533 | 1/20 | 0.98 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.98 |
| ▸ | LCK | P06239 | 1/20 | 0.98 |
| ▸ | FES | P07332 | 1/20 | 0.98 |
| ▸ | LYN | P07948 | 1/20 | 0.98 |
| ▸ | RET | P07949 | 1/20 | 0.98 |
| ▸ | IGF1R | P08069 | 1/20 | 0.98 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.98 |
| ▸ | MET | P08581 | 1/20 | 0.98 |
| ▸ | ROS1 | P08922 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ceritinib SCHEMBL30053881 | 1.00 | ALK (0.98) | ALKINSRKCNH2PLK4BUB1B | |
| Ceritinib SCHEMBL9936675 | 1.00 | ALK (0.98) | ALKINSRKCNH2PLK4BUB1B | |
| Ceritinib SCHEMBL29489147 | 0.99 | ALK (1.00) | ALKINSRKCNH2PLK4BUB1B | |
| Ceritinib SCHEMBL29349781 | 0.99 | ALK (1.00) | ALKINSRKCNH2PLK4BUB1B | |
| Ceritinib SCHEMBL1014329 | 0.99 | ALK (1.00) | ALKINSRKCNH2PLK4BUB1B | |
| SCHEMBL1545837 | 0.96 | ALK (0.94) | ALKINSRKCNH2PLK4BUB1B | |
| Ceritinib SCHEMBL17879538 | 0.94 | ALK (0.90) | ALKINSRKCNH2PLK4BUB1B | |
| Ceritinib SCHEMBL17879536 | 0.94 | ALK (0.93) | ALKINSRKCNH2PLK4BUB1B | |
| SCHEMBL24852882 | 0.94 | ALK (1.00) | ALKINSRKCNH2PLK4BUB1B | |
| Ceritinib SCHEMBL17879535 | 0.93 | ALK (0.89) | ALKINSRKCNH2PLK4BUB1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | claimed |
| WO-2025106903-A1 | THE ROLE OF MIR-15A IN DIAGNOSING AND TREATING PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) | OHIO STATE INNOVATION FOUNDATION (US) | 2025-05-22 | — | — | WO | claimed |
| WO-2024258363-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | SAHIN FIKRET (TR) | 2024-12-19 | — | — | WO | claimed |
| US-20240374610-A1 | METHOD AND PHARMACEUTICAL COMPOSITION FOR TREATING OR ALLEVIATING GLIOMAS IN A SUBJECT | ZHEJIANG UNIVERSITY (CN) | 2024-11-14 | — | — | US | claimed |
| WO-2024220648-A2 | TARGETING THE IGF-1 PATHWAY TO EXTEND ORGAN LIFESPAN | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-10-24 | — | — | WO | claimed |
| US-20240261279-A1 | METHOD FOR TREATING LUNG CANCER | Hung, Mien-Chie (TW) | 2024-08-08 | — | — | US | claimed |
| CN-111410649-B | Preparation method of ceritinib | 南京海润医药有限公司 | 2022-09-02 | — | — | CN | claimed |
| EP-4615506-A1 | USE OF GSK-3 ACTIVATIOR TO MODULATE PROTEASOME ACTIVITY TO PREVENT AGEING ASSOCIATED CONDITIONS AND DISEASES | Sahin, Fikret (TR) | 2025-09-17 | — | — | EP | disclosed |
| EP-4615869-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | Pinetree Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025106903-A1 | THE ROLE OF MIR-15A IN DIAGNOSING AND TREATING PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) | OHIO STATE INNOVATION FOUNDATION (US) | 2025-05-22 | — | — | WO | disclosed |
| US-12295955-B2 | TTP phosphorylation for the identification of personalized medicines | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2025-05-13 | — | — | US | disclosed |
| US-20250144067-A1 | PERSONALIZED STARVATION THERAPY FOR CANCER | FAETH THERAPEUTICS, INC. | 2025-05-08 | — | — | US | disclosed |
| US-20250085273-A1 | NOVEL RAPID DRUG DISCOVERY FOR SEPSIS AND AGENTS FOR USE AS SEPSIS THERAPY | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2025-03-13 | — | — | US | disclosed |
| US-20240261279-A1 | METHOD FOR TREATING LUNG CANCER | Hung, Mien-Chie (TW) | 2024-08-08 | — | — | US | disclosed |
| WO-2024102187-A1 | COMBINATION THERAPY COMPRISING BISPECIFIC ANTIBODIES COMPRISING AN NRP1 BINDING DOMAIN | PINETREE THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | WO | disclosed |
| EP-4349340-A1 | USE OF PHARMACEUTICAL COMPOSITION FOR TREATING LUNG CANCER | Hung, Mien-Chie (TW) | 2024-04-10 | — | — | EP | disclosed |
| EP-4349340-A1 | USE OF PHARMACEUTICAL COMPOSITION FOR TREATING LUNG CANCER | Hung, Mien-Chie (TW) | 2024-04-10 | — | — | EP | disclosed |
| US-20230310437-A1 | TTP PHOSPHORYLATION FOR THE IDENTIFICATION OF PERSONALIZED MEDICINES | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-10-05 | — | — | US | disclosed |
| US-11648251-B2 | TTP phosphorylation as a biomarker in targeted therapy | KING FAISAL SPECIALIST HOSPITAL & RESEARCH CENTRE (SA) | 2023-05-16 | — | — | US | disclosed |
| CN-111410649-B | Preparation method of ceritinib | 南京海润医药有限公司 | 2022-09-02 | — | — | CN | disclosed |